Ignite Creation Date:
2024-10-25 @ 8:01 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06654297
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-20
Brief Title:
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Safety and Feasibility of Neoadjuvant Camrelizumab With Palbociclibb for the Treatment of Resectable Esophageal Squamous Cell CarcinomaA Phase 1 Trial
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
he purpose of this study is to explore the safety and feasibility of anti-programmed cell death 1PD-1 immunotherapy Camrelizumab combined with cyclin-dependent kinase 46 blockade Palbociclib as a new neoadjuvant treatment regimen for patients with resectable esophageal squamous cell carcinoma ESCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None